{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:34:23Z","timestamp":1787751263813,"version":"build-2784847793"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Multimodal interventions in neuroendocrine tumors appear to have a beneficial impact on survival. Metastatic insulinoma is associated with hypoglycemia and, historically, a shortened life expectancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The authors retrospectively analyzed the clinical outcomes of patients with metastatic insulinomas treated at a tertiary care center between 2006 and 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study. The patients underwent various treatments including surgery; liver directed therapies (embolization, selective internal radiotherapy), somatostatin analogs; targeted agents (everolimus); systemic chemotherapy (capecitabine\/temozolomide; carboplatin\/etoposide); external beam radiation; and peptide receptor radiotherapy. Seven subjects died during follow-up. The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years). This compares to previous reports of median survival of about 2 years. Seven subjects are alive 1.2-12.3 years after diagnosis. Hypoglycemia was well-controlled and did not cause the deaths.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Multimodal interventions in metastatic insulinoma can be effective in managing hypoglycemia. The patients on multimodal treatments also lived a long time when considering previous published reports of median survival of just 2 years. Our findings challenge previous assumptions regarding clinical outcomes in this patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae275","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T19:16:08Z","timestamp":1730315768000},"source":"Crossref","is-referenced-by-count":4,"title":["Metastatic insulinoma\u2014outcomes in the current era"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-804X","authenticated-orcid":false,"given":"Umesh","family":"Masharani","sequence":"first","affiliation":[{"name":"University of California Department of Medicine, , San Francisco, CA 94143 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Lindsay","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center , San Francisco, CA 94143 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Moon","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center , San Francisco, CA 94143 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Paciorek","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center , San Francisco, CA 94143 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bergsland","sequence":"additional","affiliation":[{"name":"University of California Department of Medicine, , San Francisco, CA 94143 ,","place":["United States"]},{"name":"UCSF Helen Diller Family Comprehensive Cancer Center , San Francisco, CA 94143 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2025033007272477100_CIT0001","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","article-title":"Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms","volume":"58","author":"Leoncini","year":"2017","journal-title":"Endocrine"},{"key":"2025033007272477100_CIT0002","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.cgh.2018.12.017","article-title":"Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025033007272477100_CIT0003","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J Gastroenterol"},{"key":"2025033007272477100_CIT0004","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncr.21179","article-title":"Malignant insulinoma: spectrum of unusual clinical features","volume":"104","author":"Hirshberg","year":"2005","journal-title":"Cancer"},{"key":"2025033007272477100_CIT0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ando.2013.07.001","article-title":"Malignant insulinoma: recommendations for characterisation and treatment","volume":"74","author":"Baudin","year":"2013","journal-title":"Ann Endocrinol (Paris)"},{"key":"2025033007272477100_CIT0006","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00268-020-05445-x","article-title":"Malignant insulinoma: a rare form of neuroendocrine tumor","volume":"44","author":"Sada","year":"2020","journal-title":"World J Surg"},{"key":"2025033007272477100_CIT0007","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00268-005-7743-y","article-title":"Malignant metastatic insulinoma-postoperative treatment and follow-up","volume":"29","author":"Starke","year":"2005","journal-title":"World J Surg"},{"key":"2025033007272477100_CIT0008","doi-asserted-by":"crossref","first-page":"e13318","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2025033007272477100_CIT0009","first-page":"1027","article-title":"Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery","volume":"96","author":"Danforth","year":"1984","journal-title":"Surgery"},{"key":"2025033007272477100_CIT0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21037\/gs.2017.10.08","article-title":"Management of functional neuroendocrine tumors of the pancreas","volume":"7","author":"Oberg","year":"2018","journal-title":"Gland Surg"},{"key":"2025033007272477100_CIT0011","doi-asserted-by":"crossref","first-page":"e230020","DOI":"10.1530\/ERC-23-0020","article-title":"Emerging therapies for advanced insulinomas and glucagonomas","volume":"30","author":"Alexandraki","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2025033007272477100_CIT0012","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cen.13528","article-title":"Multidisciplinary management of refractory insulinomas","volume":"88","author":"Brown","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025033007272477100_CIT0013","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"2025033007272477100_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"2025033007272477100_CIT0015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American Neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"key":"2025033007272477100_CIT0016","first-page":"7","article-title":"Optimising therapeutic options for patients with advanced pancreatic neuroendocrine tumours","volume":"8","author":"Yao","year":"2012","journal-title":"Eur. J. Haematol"},{"key":"2025033007272477100_CIT0017","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"2025033007272477100_CIT0018","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12902-018-0321-8","article-title":"Clinical Management of Malignant Insulinoma: a single Institution\u2019s experience over three decades","volume":"18","author":"Yu","year":"2018","journal-title":"BMC Endocr Disord"},{"key":"2025033007272477100_CIT0019","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2011-1563","article-title":"Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy","volume":"96","author":"van Schaik","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2025033007272477100_CIT0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/EJE-19-0989","article-title":"Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study","volume":"182","author":"Veltroni","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"2025033007272477100_CIT0021","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diabet.2008.01.013","article-title":"Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: a retrospective 35-year study of 12 patients","volume":"34","author":"Begu-Le Corroller","year":"2008","journal-title":"Diabetes Metab"},{"key":"2025033007272477100_CIT0022","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjsurg.2020.08.003","article-title":"Comparison of benign and malignant insulinoma","volume":"221","author":"Sada","year":"2021","journal-title":"Am J Surg"},{"key":"2025033007272477100_CIT0023","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in Neuroendocrine tumors","volume":"139","author":"Riihimaki","year":"2016","journal-title":"Int J Cancer"},{"key":"2025033007272477100_CIT0024","doi-asserted-by":"crossref","first-page":"e220321","DOI":"10.1530\/ERC-22-0321","article-title":"Aggressive versus indolent insulinomas: new clinicopathological insights","volume":"30","author":"Hackeng","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2025033007272477100_CIT0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13023-022-02370-1","article-title":"Analysis of 55 patients with multiple endocrine neoplasia type 1-associated insulinoma from a single center in China","volume":"17","author":"Zhao","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2025033007272477100_CIT0026","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","article-title":"Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study","volume":"66","author":"Service","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"2025033007272477100_CIT0027","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clinre.2018.08.005","article-title":"Life expectancy in pancreatic neuroendocrine cancer","volume":"43","author":"Brooks","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025033007272477100_CIT0028","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2025033007272477100_CIT0029","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025033007272477100_CIT0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","article-title":"[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well differentiated Gastroenteropancreatic Neuroendocrine tumors: primary analysis of the phase 3 Randomized NETTER-2 study","volume":"42","author":"Singh","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025033007272477100_CIT0031","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025033007272477100_CIT0032","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjsurg.2003.04.007","article-title":"Management of neuroendocrine liver metastases","volume":"187","author":"Sutcliffe","year":"2004","journal-title":"Am J Surg"},{"key":"2025033007272477100_CIT0033","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"2025033007272477100_CIT0034","doi-asserted-by":"crossref","first-page":"906012","DOI":"10.3389\/fendo.2022.906012","article-title":"Case report: hypoglycemia due to metastatic insulinoma in insulin-dependent type 2 diabetes successfully treated with 177 Lu-DOTATATE","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025033007272477100_CIT0035","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025033007272477100_CIT0036","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.123.265894","article-title":"Peptide receptor radionuclide therapy is effective for clinical control of symptomatic metastatic insulinoma: a long-term retrospective analysis","volume":"65","author":"Friebe","year":"2024","journal-title":"J Nucl Med"},{"key":"2025033007272477100_CIT0037","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1507\/endocrj.EJ18-0542","article-title":"The clinical course and potential underlying mechanisms of everolimus-induced hyperglycemia","volume":"66","author":"Tanimura","year":"2019","journal-title":"Endocr J"},{"key":"2025033007272477100_CIT0038","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/js.2017-00475","article-title":"Everolimus directly suppresses insulin secretion independently of cell growth inhibition","volume":"2","author":"Suzuki","year":"2018","journal-title":"J Endocr Soc"},{"key":"2025033007272477100_CIT0039","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-12-1101","article-title":"Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia","volume":"168","author":"Bernard","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2025033007272477100_CIT0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","author":"Kulke","year":"2009","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae275\/60242783\/oyae275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae275\/60242783\/oyae275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:14:41Z","timestamp":1743452081000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae275\/7852818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae275","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,30]]},"article-number":"oyae275"}}